Cooperative Agreement U01CA293853
Award Date
9/19/24
Completion Date
8/31/29
Dollars Obligated
$591K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Cooperative Agreement
Place of Performance
Irwindale, CA 91010, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $487,542 to the Beckman Research Institute of the City of Hope to conduct research aimed at understanding the role of mitochondrial RNA methylation in acute myeloid leukemia (AML), particularly for high-risk AML subtypes. The key objectives are to determine the functional importance of the mitochondrial methyltransferase METTL17 in AML pathogenesis, dissect...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope. The $734,435 grant, awarded on March 10, 2025, aims to develop a novel combination therapy targeting AMP synthesis to overcome resistance to BH3 mimetic drugs in acute myeloid leukemia (AML). The key objectives are to: 1) correlate ADSS2 levels with BH3 mimetic responsiveness in primary AML cells and determine if ADSS2...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Beckman Research Institute of the City of Hope provides $738,698 to develop a novel combination therapy for treating relapsed and refractory acute myelogenous leukemia (AML) in older patients. The key product being developed is a targeted radiotherapy approach that combines total marrow irradiation (TMLI) with an anti-CD38 targeted alpha therapy (TAT) using the monoclonal antibody...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $458,698 to the Regents of the University of Michigan to conduct research aimed at understanding the fundamental biological mechanisms underlying acute myeloid leukemia (AML) relapse. The research will focus on identifying novel gene drivers that confer therapy resistance and contribute to the competitive regrowth of leukemic cells after initial treatment, which is a major barrier...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $542,663 to The University of Texas M.D. Anderson Cancer Center to conduct preclinical research on novel therapies for acute myeloid leukemia (AML). The research aims to evaluate the efficacy of BRG1/BRM antagonists, such as the inhibitor FHD-286 and the degrader AU15330, in overcoming resistance to menin inhibitors in AML with MLL rearrangement or mutant NPM1. The studies...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports fundamental research aimed at understanding the biological mechanisms underlying acute myeloid leukemia (AML) development and progression. The $487,973 award to The Leland Stanford Junior University will fund a 5-year project investigating the role of pre-leukemic hematopoietic stem cells (pHSCs) in AML pathogenesis. The research will explore the clonal evolution, kinetics, and cell...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Trustees of Columbia University in the City of New York provides $2,775,137 to conduct research on the role of aging-related factors in the transformation of pre-leukemic conditions to acute myeloid leukemia (AML). The key objectives are to 1) establish how transcriptional deregulation, inflammatory signals, and stromal niche interactions promote clonal outgrowth of pre-leukemic...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Case Western Reserve University to investigate a novel combination therapy approach for acute myeloid leukemia (AML). The $491,357 award, granted on March 15, 2025, aims to establish the mechanistic role of mTOR hyperactivation as a chemosensitizer for AML. Key objectives include mapping mitochondrial respiratory defects, identifying AML cell susceptibility to metabolic...
This $878,400 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Biology Research program (CFDA 93.396) will fund research characterizing vitamin B6 pathway dependency in acute myeloid leukemia (AML) at Cold Spring Harbor Laboratory from January 2023 through December 2027. The research aims to further the understanding of the underlying mechanisms of AML by studying abnormal vitamin pathways and metabolic programming...
The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), has awarded a $683,472 Project Grant to the University of Cincinnati to advance pharmacodynamically directed targeted therapy for acute myeloid leukemia (AML). The 5-year project aims to transition the DHODH inhibitor HOSU-53 into clinical trials, starting with a Phase 1 trial in 2025 to evaluate the compound's pharmacokinetics, pharmacodynamics, and ability to eliminate specific AML cell clones....